Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner

Atherosclerosis--an inflammatory disease

Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725

Standards of Medical Care in Diabetes—2012

(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240

Mechanisms Underlying Endothelial Dysfunction in Diabetes Mellitus

Hink, U., Li, H., Mollnau, H., Oelze, M., Matheis, E., Hartmann, M., Skatchkov, M. P., Thaiss, F., Stahl, R. A. K., Warnholtz, A., et al. (2001) · Circulation Research · doi:10.1161/01.res.88.2.e14 · Cited by 1,191

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057

Mechanisms of Increased Vascular Superoxide Production in Human Diabetes Mellitus

Guzik, T. J., Mussa, S., Gastaldi, D., Sadowski, J., Ratnatunga, C., Pillai, R. G., & Channon, K. M. (2002) · Circulation · doi:10.1161/01.cir.0000012748.58444.08 · Cited by 979

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease

Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548

Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus

Heitzer, T., Krohn, K., Albers, S., & Meinertz, T. (2000) · Diabetologia · doi:10.1007/s001250051551 · Cited by 427

Noninvasive assessment of coronary flow velocity and coronary flow velocity reserve in the left anterior descending coronary artery by Doppler echocardiography

Hozumi, T., Yoshida, K., Akasaka, T., Asami, Y., Ogata, Y., Takagi, T., Kaji, S., Kawamoto, T., Ueda, Y., & Morioka, S. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00389-1 · Cited by 425

GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art

Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582

The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways

Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509

Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications

Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential

Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299

Emerging Role of cAMP/AMPK Signaling

Aslam, M., & Ladilov, Y. (2022) · Cells · doi:10.3390/cells11020308 · Cited by 241

International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases

Dessauer, C. W., Watts, V. J., Ostrom, R. S., Conti, M., Dove, S., & Seifert, R. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.013078 · Cited by 201

GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171

Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6

Nauck, M. A., & Quast, D. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645566 · Cited by 118

Role of PI3K in the Progression and Regression of Atherosclerosis

Zhao, Y., Qian, Y., Sun, Z., Shen, X., Cai, Y., Li, L., & Wang, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.632378 · Cited by 104

Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options

Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Loffredo, G., Rinaldi, L., Catalini, C., Gjeloshi, K., Albanese, G., Di Martino, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092274 · Cited by 98

Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction

Qin, Q., Delrio, S., Wan, J., Widmer, R. J., Cohen, P., Lerman, L. O., & Lerman, A. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.12.001 · Cited by 95

Brain GLP-1/IGF-1 Signaling and Autophagy Mediate Exendin-4 Protection Against Apoptosis in Type 2 Diabetic Rats

Candeias, E., Sebastião, I., Cardoso, S., Carvalho, C., Santos, M. S., Oliveira, C. R., Moreira, P. I., & Duarte, A. I. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0622-3 · Cited by 89

Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output

Liu, J., Yang, K., Yang, J., Xiao, W., Le, Y., Yu, F., Gu, L., Lang, S., Tian, Q., Jin, T., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.037 · Cited by 85

Exendin‐4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant

Yap, M. K. K., & Misuan, N. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13169 · Cited by 82

Coffee and Endothelial Function: A Coffee Paradox?

Higashi, Y. (2019) · Nutrients · doi:10.3390/nu11092104 · Cited by 75

GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far

Pedrosa, M. R., Franco, D. R., Gieremek, H. W., Vidal, C. M., Bronzeri, F., de Cassia Rocha, A., de Carvalho Cara, L. G., Fogo, S. L., & Eliaschewitz, F. G. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01062-2 · Cited by 68

The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: a mini-review of the potential mechanisms

Ribeiro-Silva, J. C., Tavares, C. A. M., & Girardi, A. C. C. (2023) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2023.102355 · Cited by 71

Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms

Vergès, B., Aboyans, V., Angoulvant, D., Boutouyrie, P., Cariou, B., Hyafil, F., Mohammedi, K., & Amarenco, P. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01686-3 · Cited by 72

AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases

Lu, Q., Li, X., Liu, J., Sun, X., Rousselle, T., Ren, D., Tong, N., & Li, J. (2019) · Bioscience Reports · doi:10.1042/bsr20181995 · Cited by 69

Exendin-4 inhibits structural remodeling and improves Ca 2+ homeostasis in rats with heart failure via the GLP-1 receptor through the eNOS/cGMP/PKG pathway

Chen, J., Wang, D., Wang, F., Shi, S., Chen, Y., Yang, B., Tang, Y., & Huang, C. (2017) · Peptides · doi:10.1016/j.peptides.2017.02.008 · Cited by 64

Therapeutic application of GPR119 ligands in metabolic disorders

Yang, J. W., Kim, H. S., Choi, Y., Kim, Y., & Kang, K. W. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13062 · Cited by 63

Liraglutide for Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease

Caruso, P., Maiorino, M. I., Longo, M., Porcellini, C., Matrone, R., Selvaggio, L. D., Gicchino, M., Carbone, C., Scappaticcio, L., Bellastella, G., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.1545 · Cited by 65

Treatment of Obesity in Mitigating Metabolic Risk

Heffron, S. P., Parham, J. S., Pendse, J., & Alemán, J. O. (2020) · Circulation Research · doi:10.1161/circresaha.119.315897 · Cited by 62

A GLP-1 analog lowers ER stress and enhances protein folding to ameliorate homocysteine-induced endothelial dysfunction

Cheng, C. K., Luo, J., Lau, C. W., Cho, W. C. S., Ng, C., Ronald, C. W., Tian, X. Y., & Huang, Y. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00589-x · Cited by 58

The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)

Hullon, D., Subeh, G. K., Volkova, Y., Janiec, K., Trach, A., & Mnevets, R. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02607-w · Cited by 59

Exendin-4 ameliorates high glucose-induced fibrosis by inhibiting the secretion of miR-192 from injured renal tubular epithelial cells

Jia, Y., Zheng, Z., Guan, M., Zhang, Q., Yang, L., Wang, L., & Xue, Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0084-3 · Cited by 55

Vascular (dys)function in the failing heart

Liberale, L., Duncker, D. J., Hausenloy, D. J., Kraler, S. C., Bøtker, H. E., Podesser, B. K., Heusch, G., & Kleinbongard, P. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01163-w · Cited by 58

The metabolite GLP‐1 (9‐36) is neuroprotective and anti‐inflammatory in cellular models of neurodegeneration

Li, Y., Glotfelty, E. J., Karlsson, T. E., Fortuno, L. V., Harvey, B. K., & Greig, N. H. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15521 · Cited by 47

The Expanding Role of GLP-1 Receptor Agonists: Advancing Clinical Outcomes in Metabolic and Mental Health

Qassab, M. A., Mneimneh, M., Jradi, A., Derbas, B., Dabboussi, D., Baini, J. K., Katrib, N., Chaarani, N., Attieh, P., Kanaan, A., et al. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040285 · Cited by 61

AMPK pathway: an emerging target to control diabetes mellitus and its related complications

Kakoti, B. B., Alom, S., Deka, K., & Halder, R. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01420-8 · Cited by 50

Fucoidan ameliorates pancreatic β‐cell death and impaired insulin synthesis in streptozotocin‐treated β cells and mice via a Sirt‐1‐dependent manner

Yu, W., Chen, Y., Hwang, P., Chen, T., & Chou, T. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700136 · Cited by 45

Exenatide exhibits anti‐inflammatory properties and modulates endothelial response to tumor necrosis factor α‐mediated activation

Garczorz, W., Gallego-Colón, E., Kosowska, A., Kłych‐Ratuszny, A., Woźniak, M., Marcol, W., Niesner, K. J., & Francuz, T. (2017) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12317 · Cited by 43

Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms

Savarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 45

Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities

Shao, S., Zhang, X., Xu, Q., Pan, R., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108270 · Cited by 42

The role of glucagon‐like peptide‐1 receptor agonists in metabolic dysfunction‐associated steatohepatitis

Abdelmalek, M. F., Harrison, S. A., & Sanyal, A. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15524 · Cited by 45

Glucose-Dependent Insulinotropic Polypeptide Suppresses Peripheral Arterial Remodeling in Male Mice

Mori, Y., Kushima, H., Koshibu, M., Saito, T., Hiromura, M., Kohashi, K., Terasaki, M., Seino, Y., Yamada, Y., & Hirano, T. (2018) · Endocrinology · doi:10.1210/en.2018-00336 · Cited by 41

Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway

Ke, J., Liu, Y., Yang, J., Lu, R., Tian, Q., Hou, W., Wang, G., Wei, R., & Hong, T. (2017) · Scientific Reports · doi:10.1038/srep41085 · Cited by 38

Incretin drugs as modulators of atherosclerosis

Gallego-Colon, E., Wojakowski, W., & Francuz, T. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.09.011 · Cited by 35

GLP-1 Receptor Agonists and Myocardial Perfusion: Bridging Mechanisms to Clinical Outcomes

Karakasis, P., Patoulias, D., Theofilis, P., Pamporis, K., Sagris, Μ., Vlachakis, P. K., Koufakis, T., Antoniadis, A. P., & Fragakis, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073050 · Cited by 38

Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes

Lyu, J., Imachi, H., Fukunaga, K., Sato, S., Kobayashi, T., Dong, T., Saheki, T., Matsumoto, M., Iwama, H., Zhang, H., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.12.015 · Cited by 36

GLP-1 receptor agonists and inflammatory pathway modulation: Dual targeting of metabolic and immune dysfunction in insulin resistance

Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35

Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists

Wu, Q., Li, D., Huang, C., Zhang, G., Wang, Z., Liu, J., Yu, H., Song, B., Zhang, N., Li, B., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113517 · Cited by 32

Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease?

Bakbak, E., Terenzi, D. C., Trac, J. Z., Teoh, H., Quan, A., Glazer, S. A., Rotstein, O. D., Al-Omran, M. A., Verma, S., & Hess, D. A. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09669-7 · Cited by 32

Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients

Correale, M., Lamacchia, O., Ciccarelli, M., Dattilo, G., Tricarico, L., & Brunetti, N. D. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10157-y · Cited by 29

Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists

Madsbad, S., & Holst, J. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac112 · Cited by 37

GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review

Jarade, C., Zolotarova, T., Moiz, A., & Eisenberg, M. J. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102789 · Cited by 31

Liraglutide ameliorates palmitate-induced oxidative injury in islet microvascular endothelial cells through GLP-1 receptor/PKA and GTPCH1/eNOS signaling pathways

Le, Y., Wei, R., Yang, K., Lang, S., Gu, L., Liu, J., Hong, T., & Yang, J. (2019) · Peptides · doi:10.1016/j.peptides.2019.170212 · Cited by 28

Therapeutic potential of GLP-1 receptor agonists in diabetes and cardiovascular disease: mechanisms and clinical implications

Zhang, X., Cao, C., Zheng, F., Liu, C., & Tian, X. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07670-9 · Cited by 27

Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease

Wang, T., Ding, J., Cheng, X., Yang, Q., & Hu, P. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1396656 · Cited by 29

Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes

Aung, M. M., Slade, K., Freeman, L. A. R., Kos, K., Whatmore, J. L., Shore, A. C., & Gooding, K. M. (2019) · Diabetologia · doi:10.1007/s00125-019-4918-x · Cited by 27

Effects of glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in high-risk type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Chen, X., Zhang, X., Xiang, X., Fang, X., & Feng, S. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01497-4 · Cited by 26

Mechanistic insights and emerging therapeutic strategies targeting endothelial dysfunction in cardiovascular diseases

Heo, K., Phan, L. P., Le, N. T. T., & Jin, Y. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01542-4 · Cited by 29

Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection

Battistoni, A., Piras, L., Tartaglia, N., Carrano, F. M., Vitis, C. D., & Barbato, E. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1669685 · Cited by 31

Liraglutide, a Glucagon-like Peptide-1 Receptor Agonist, Attenuates Development of Cardiac Allograft Vasculopathy in a Murine Heart Transplant Model

Wang, Z., Wang, M., Hu, X.-F., Li, Y., Ma, D., Li, S.-L., Zhao, G., Xie, Y., Shu, Y., & Yang, J. (2018) · Transplantation · doi:10.1097/tp.0000000000002448 · Cited by 26

HFpEF and MASLD: converging mechanisms and clinical implications

Capone, F., Häseli, S. P., Liu, L., Strocchi, S., Langenberg, C., Lusis, A. J., Pietzner, M., Muoio, D. M., Rider, O. J., Raman, B., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01257-z · Cited by 35

The potential role of Tirzepatide as adjuvant therapy in countering colistin-induced nephro and neurotoxicity in rats via modulation of PI3K/p-Akt/GSK3-β/NF-kB p65 hub, shielding against oxidative and endoplasmic reticulum stress, and activation of p-CREB/BDNF/TrkB cascade

Hassan, N. F., Ragab, D., Ibrahim, S. G., Elgalil, M. M. A., Abd-El-Hamid, A. H., Hamed, D. M., William, M. M., & Salem, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112308 · Cited by 24

When Good Guys Turn Bad: Bone Marrow’s and Hematopoietic Stem Cells’ Role in the Pathobiology of Diabetic Complications

Vinci, M. C., Gambini, E., Bassetti, B., Genovese, S., & Pompilio, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113864 · Cited by 24

Liraglutide restores angiogenesis in palmitate-impaired human endothelial cells through PI3K/Akt-Foxo1-GTPCH1 pathway

Ke, J., Wei, R., Yu, F., Zhang, J., & Hong, T. (2016) · Peptides · doi:10.1016/j.peptides.2016.10.009 · Cited by 24

Exendin-4 Preserves Blood-Brain Barrier Integrity via Glucagon-Like Peptide 1 Receptor/Activated Protein Kinase-Dependent Nuclear Factor-Kappa B/Matrix Metalloproteinase-9 Inhibition After Subarachnoid Hemorrhage in Rat

Xie, Z., Enkhjargal, B., Matei, N., Wu, L., Zhu, Q., Zhang, T., Tang, J., & Zhang, J. H. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.750726 · Cited by 24

Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity

Yazıcı, D., Eser, H. Y., Kiyici, S. K., Sancak, S., Sezer, H., Uygur, M., & Yumuk, V. (2022) · Obesity Facts · doi:10.1159/000526808 · Cited by 26

Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists

Ji, Q. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.013 · Cited by 21

The Effects of Exenatide and Metformin on Endothelial Function in Newly Diagnosed Type 2 Diabetes Mellitus Patients: A Case–Control Study

Hu, Y., Liu, J., Wang, G., & Xu, Y. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0435-z · Cited by 21

Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction

Suhrs, H. E., Raft, K. F., Bove, K. B., Madsbad, S., Holst, J. J., Zander, M., & Prescott, E. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.12.005 · Cited by 21

A primer on obesity-related cardiomyopathy

Samson, W. K., Yosten, G. L. C., & Remme, C. A. (2021) · Physiological Reviews · doi:10.1152/physrev.00023.2021 · Cited by 23

Glucagon-like peptide-1 receptor activation maintains extracellular matrix integrity by inhibiting the activity of mitogen-activated protein kinases and activator protein-1

Peng, Y., Lin, H., Tian, S., Liu, S., Li, J., Lv, X., Chen, S., Zhao, L., Pu, F., Chen, X., et al. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.10.034 · Cited by 19

Effects of L-arginine supplementation on fat deposition and meat quality in growing lambs: Interactions with gut microbiota and metabolic signalling pathways

Kang, L., Li, X., Zhao, X., Liu, T., Jin, Y., & Duan, Y. (2025) · Food Chemistry · doi:10.1016/j.foodchem.2025.143677 · Cited by 18

Liraglutide Accelerates Ischemia‐Induced Angiogenesis in a Murine Diabetic Model

Zhu, Y., Li, Y., Ma, Y., Zhang, X., Du, X., Gao, J., Ding, N., Wang, L., Ni, C., Luo, M., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.026586 · Cited by 18

Ethyl Rosmarinate Protects High Glucose-Induced Injury in Human Endothelial Cells

Shen, Y., Wang, L., Zhang, B., Hu, Q.-M., Wang, P., He, B.-Q., Bao, G., Liang, J., & Wu, F. (2018) · Molecules · doi:10.3390/molecules23123372 · Cited by 17

Effect of eNOS on Ischemic Postconditioning-Induced Autophagy against Ischemia/Reperfusion Injury in Mice

Shao, J., Miao, C., Geng, Z., Gu, M.-H., Wu, Y., & Li, Q. (2019) · BioMed Research International · doi:10.1155/2019/5201014 · Cited by 17

A synthetic peptide AWRK6 ameliorates metabolic associated fatty liver disease: involvement of lipid and glucose homeostasis

Jin, L., Sun, Y., Li, Y., Zhang, H., Yu, W., Li, Y., Xin, Y., Alsareii, S. A., Wang, Q., & Zhang, D. (2021) · Peptides · doi:10.1016/j.peptides.2021.170597 · Cited by 17

Remote ischemic conditioning protects against endothelial ischemia-reperfusion injury via a glucagon-like peptide-1 receptor-mediated mechanism in humans

Verouhis, D., Saleh, N., Settergren, M., Sörensson, P., Gourine, A. V., & Pernow, J. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.09.061 · Cited by 16

Microvascular Density and Circulating Endothelial Progenitor Cells Before and After Treatment with Incretin Mimetics in Diabetic Patients

Ciuceis, C. D., Rosei, C. A., Rossini, C., Caletti, S., Coschignano, M. A., Ferrari‐Toninelli, G., Ragni, G., Cappelli, C., Cerudelli, B., Airó, P., et al. (2018) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-018-0279-7 · Cited by 16

GLP-1/GLP-1R axis: from metabolism (obesity and T2DM) to immunity

Kumar, V. (2025) · Open Biology · doi:10.1098/rsob.240303 · Cited by 17

Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox Balance

Hardoňová, M., Šiarnik, P., Siváková, M., Sucha, B., Penesová, A., Rádiková, Ž., Havranová, A., Imrich, R., Vlček, M., Žitňanová, I., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311162 · Cited by 15

Glucagon-like Peptide-1 Receptor Agonists

Jeon, J. Y., & Kim, H. J. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_14 · Cited by 16

Pleiotropic effects of GLP‐1 receptor agonists on peripheral artery disease: Is there any hope?

Caruso, P., Maiorino, M. I., Bellastella, G., Esposito, K., & Giugliano, D. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3627 · Cited by 13

Sitagliptin Accelerates Endothelial Regeneration after Vascular Injury Independent from GLP1 Receptor Signaling

Remm, F., Kränkel, N., Lener, D., Drucker, D. J., Sopper, S., & Brenner, C. (2018) · Stem Cells International · doi:10.1155/2018/5284963 · Cited by 14

Molecular damage associated with ageing drives inflammation in cardiovascular disease

Herman, A. B., Candia, J., Wilson, D., Donegà, S., Picard, M. A., & Ferrucci, L. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01253-3 · Cited by 14

Evaluation of glucagon-like peptide-1 receptor expression in nondiabetic and diabetic atherosclerotic mice using PET tracer 68Ga-NODAGA-exendin-4

Ståhle, M. R., Hellberg, S., Virta, J., Liljenbäck, H., Metsälä, O., Li, X., Jauhiainen, M., Saukko, P. J., Ylä‐Herttuala, S., Nuutila, P., et al. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00465.2020 · Cited by 12

An updated review on therapeutic strategies in coronary microvascular dysfunction

Khandkar, C., Rehan, R., Ravindran, J., & Yong, A. S. C. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133128 · Cited by 12

Intermedin protects peritubular capillaries by inhibiting eNOS uncoupling through AMPK/GTPCH-I/BH4 pathway and alleviate CKD following AKI

Lin, H., Pan, J., Zhang, J., He, Y., Yuan, G., Niu, D., Han, W., Han, X., Fan, L., Bai, X., et al. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.04.015 · Cited by 11

Madagascine Induces Vasodilatation via Activation of AMPK

Chen, D., Lv, B., Kobayashi, S., Xiong, Y., Sun, P., Lin, Y., Genovese, S., Epifano, F., Hou, S., Tang, F., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00435 · Cited by 11

Non-targeted metabolomic analysis predicts the therapeutic effects of exenatide on endothelial injury in patients with type 2 diabetes

Yang, J., Le, Y., Wei, T., Wang, K., Yang, K., Xiao, W., Hong, T., & Wei, R. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107797 · Cited by 10

Cardiovascular effects of antiobesity drugs: are the new medicines all the same?

Cataldi, M., Cignarelli, A., Giallauria, F., Muscogiuri, G., Barrea, L., Savastano, S., & Colao, A. A. L. (2020) · International Journal of Obesity Supplements · doi:10.1038/s41367-020-0015-3 · Cited by 11

Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan‐L trial

Giorgino, F., Shaunik, A., Liu, M., & Saremi, A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13857 · Cited by 9

The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults

Nilsson, M., Bove, K. B., Suhrs, H. E., Hermann, T. S., Madsbad, S., Holst, J. J., Prescott, E., & Zander, M. (2019) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2019.01.004 · Cited by 10

Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients

Madsbad, S. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1615444 · Cited by 10

GLP-1R agonist therapy and vaccine response: Neglected implications

van Niekerk, G., Coelmont, L., Alpizar, Y. A., Kelchtermans, L., Broeckhoven, E., & Dallmeier, K. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.07.006 · Cited by 10

Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide

Odigwe, C. I., Mulyala, R. R., Malik, H., Ruiz, B., Riad, M., Sayiadeh, M. A., Honganur, S., Parks, A., Rahman, M. U., & Lakkis, N. M. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100518 · Cited by 9

Outcomes of GLP-1 receptor agonist use following ischemic stroke: a propensity score-matched real-world analysis

Rai, P., Bathla, G., Praveen, N., Gopikonda, S. S., Chen, H. A., Salim, H. A., Azzam, A. Y., Essibayi, M. A., Altschul, D., Dmytriw, A. A., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13470-w · Cited by 9

Incretins-Based Therapies and Their Cardiovascular Effects: New Game-Changers for the Management of Patients with Diabetes and Cardiovascular Disease

Bernardini, F., Nusca, A., Coletti, F., Porta, Y. L., Piscione, M., Vespasiano, F., Mangiacapra, F., Ricottini, E., Melfi, R., Cavallari, I., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071858 · Cited by 8

Obesity, cardiovascular and cerebrovascular disease: the role of GLP-1 receptor agonists

Tirandi, A., Montecucco, F., Carbone, F., & Liberale, L. (2024) · Polish Archives of Internal Medicine · doi:10.20452/pamw.16658 · Cited by 8

Exendin‑4 reverses endothelial dysfunction in mice fed a high‑cholesterol diet by a GTP cyclohydrolase‑1/tetrahydrobiopterin pathway

Tang, Z., Liu, L., Guo, Y., Deng, G., Chen, M., & Wei, J. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9345 · Cited by 8

Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists

Song, R., Qian, H., Wang, Y., Li, Q., Li, D., Chen, J., Yang, J., Zhong, J., Yang, H., Min, X., et al. (2022) · Journal of Diabetes Research · doi:10.1155/2022/4554996 · Cited by 8

Role of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in Patients with Chronic Heart Failure

Llongueras-Espí, P., García‐Romero, E., Colet, J. C., & González‐Costello, J. (2025) · Biomolecules · doi:10.3390/biom15091342 · Cited by 9

Medical and Surgical Obesity Treatments and Atherosclerosis: Mechanisms beyond Typical Risk Factors

Bostrom, J., Mottel, B. H., & Heffron, S. P. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00961-0 · Cited by 7

The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease

Guo, Z. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00609-1 · Cited by 7

Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans

Koska, J., Sands, M., Burciu, C., D’Souza, K. M., Raravikar, K., Liu, J., Truran, S., Franco, D. A., Schwartz, E. A., Schwenke, D. C., et al. (2015) · Diabetes · doi:10.2337/db14-0976 · Cited by 174

Role of GLP-1 receptor agonists in endothelial function

Erdogdu, Ö. (2012) · Figshare

[Effects of GLP-1 Agonist Exenatide on Cardiac Diastolic Function and Vascular Endothelial Function in Diabetic Patients].

Wang, X.-H., Han, L.-N., Yu, Y., Wang, C., Wang, B., Wen, X., Huang, H., & Jing, X. (2015) · PubMed · Cited by 7

Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo

Nathanson, D., Erdogdu, Ö., Pernow, J., Zhang, Q., & Nyström, T. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.07.003 · Cited by 51

Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus

Torimoto, K., Okada, Y., Mori, H., Otsuka, T., Kawaguchi, M., Matsuda, M., Kuno, F., Sugai, K., Sonoda, S., Hajime, M., et al. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0188-1 · Cited by 43